What is the appropriate dosing regimen for donepezil (Aricept)?

How to Dose Donepezil

Start donepezil at 5 mg once daily at bedtime, then increase to 10 mg daily after 4-6 weeks based on tolerability; for patients with moderate to severe Alzheimer's disease who require higher dosing, escalate to 23 mg daily only after at least 3 months on 10 mg, using a 4-week titration period (either 15 mg daily or alternating 10/23 mg) to minimize cholinergic side effects. 1, 2

Standard Dosing Algorithm

Initial Dosing (All Severity Levels)

• Starting dose: 5 mg once daily at bedtime 1, 3
• Timing: Can be taken without regard to meals 1
• Duration at starting dose: 4-6 weeks before escalation 3

First Dose Escalation

• Target dose: 10 mg once daily 1, 4
• Rationale: The 10 mg dose demonstrates significantly better cognitive improvement on MMSE scores compared to 5 mg (Hedges' g: 2.27 vs 2.09) 4
• When to escalate: After patient tolerates 5 mg for 4-6 weeks 3

High-Dose Escalation (Moderate to Severe AD Only)

Eligibility criteria:

• Patient has moderate to severe Alzheimer's disease
• Currently on stable 10 mg dose for at least 3 months
• Showing inadequate response or declining function 2, 5

Titration method (choose one):

1. Preferred approach: 15 mg daily for 4 weeks, then increase to 23 mg 2
2. Alternative approach: Alternate between 10 mg and 23 mg daily for 4 weeks, then switch to 23 mg daily 2
3. Not recommended: Direct escalation from 10 mg to 23 mg (significantly higher risk of nausea and cholinergic side effects) 2

The titration groups showed significantly fewer cases of nausea compared to direct escalation in a 2019 randomized trial 2.

Special Populations

Hepatic Impairment

• Mild to moderate cirrhosis: No dose adjustment required, though clearance decreases by 20% 1
• Monitor more closely for adverse effects

Renal Impairment

• No dose adjustment needed even in moderate to severe renal impairment (CrCl <22 mL/min) 1

Elderly Patients

• No dose adjustment required - plasma concentrations in elderly AD patients are comparable to young healthy volunteers 1

Key Pharmacokinetic Considerations

• Half-life: ~70 hours, allowing once-daily dosing 1
• Time to steady state: 15 days 1
• Peak concentration: 3-4 hours after administration 1
• Protein binding: 96% (primarily albumin) 1

Common Pitfalls to Avoid

1. Escalating too quickly: The 70-hour half-life means steady state takes 15 days - rushing dose increases before this period increases side effects without additional benefit 1

2. Skipping the 10 mg dose: Some clinicians may want to jump from 5 mg to 23 mg in severe disease - this dramatically increases cholinergic side effects 2

3. Using 23 mg in mild-moderate disease: The 23 mg dose is only FDA-approved and studied for moderate to severe AD 1, 5

4. Discontinuing for mild GI symptoms: Nausea, diarrhea, and anorexia are most common during initiation and typically resolve without dose modification 6

5. Not monitoring cardiac patients: Use caution in patients with bradycardia or conduction abnormalities due to cholinergic effects 7

Adverse Effect Profile

Most common (dose-related):

• Nausea, diarrhea, anorexia, vomiting 3, 6
• Insomnia, muscle cramps, fatigue 7
• Syncope (monitor in elderly) 7

Critical difference from tacrine: No hepatotoxicity reported with donepezil - liver function monitoring not required 3, 6

Duration of Treatment

Long-term data supports use for up to 4.9 years, with initial improvement in cognition during the first 6-9 months, followed by slower decline than predicted for untreated patients 6. The 2008 guideline notes that while improvements are statistically significant, clinical importance may be modest 8.